Sugi Predict

Sugi Predict / Compounds / SCHEMBL24316159

SCHEMBL24316159

SCHEMBL24316159

CCCCCCCCCCCC(=O)OC[C@H]1C(=O)N2[C@H](CN(Cc3cccc4ncccc34)C(=O)[C@@H]2Cc2ccc(O)cc2)N1C(=O)NCc1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
▸ CTNNB1 P35222 2/20 0.51
▸ TCF7 P36402 2/20 0.51
▸ CLPP Q16740 2/20 0.51
▸ BCL9 O00512 1/20 0.51
▸ TCF4 P15884 1/20 0.51
▸ CREBBP Q92793 1/20 0.51
▸ CYP3A4 P08684 17/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24315558 0.92 CTNNB1 (0.52) CTNNB1TCF7CLPPBCL9TCF4
SCHEMBL24315609 0.92 CLPP (0.61) CTNNB1TCF7CLPPBCL9TCF4
SCHEMBL24315628 0.90 CTNNB1 (0.49) CTNNB1TCF7CLPPBCL9TCF4
SCHEMBL26451028 0.86 CLPP (0.59) CTNNB1TCF7CLPPBCL9TCF4
SCHEMBL29515574 0.84 CLPP (0.61) CTNNB1TCF7CLPPBCL9TCF4
SCHEMBL24315555 0.84 CLPP (0.61) CTNNB1TCF7CLPPBCL9TCF4
SCHEMBL24315590 0.82 CTNNB1 (0.50) CTNNB1TCF7CLPPBCL9TCF4
SCHEMBL24315608 0.81 CLPP (0.59) CTNNB1TCF7CLPPBCL9TCF4
SCHEMBL26452418 0.80 CLPP (0.52) CTNNB1TCF7CLPPBCL9TCF4
SCHEMBL24315556 0.80 CLPP (0.57) CTNNB1TCF7CLPPBCL9TCF4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230374020-A1 SUBSTITUTED IMIDAZO[l,2-a]PYRAZINES AND PYRAZINO[l,2-a] PYRIMIDINES AS TOPICAL AGENTS FOR DERMATOLOGICAL APPLICATIONS Genesis Molecular Technologies, Inc. 2023-11-23 — — US disclosed
US-20230374020-A1 SUBSTITUTED IMIDAZO[l,2-a]PYRAZINES AND PYRAZINO[l,2-a] PYRIMIDINES AS TOPICAL AGENTS FOR DERMATOLOGICAL APPLICATIONS Genesis Molecular Technologies, Inc. 2023-11-23 — — US disclosed
US-11639356-B2 Substituted imidazo[1,2-a]pyrazines and pyrazino[1,2-a]pyrimidines as topical agents for dermatological applications Genesis Molecular Technologies, Inc. (US) 2023-05-02 — — US disclosed
US-11639356-B2 Substituted imidazo[1,2-a]pyrazines and pyrazino[1,2-a]pyrimidines as topical agents for dermatological applications Genesis Molecular Technologies, Inc. (US) 2023-05-02 — — US disclosed
US-20220106320-A1 TOPICAL AGENTS FOR DERMATOLOGICAL APPLICATIONS Genesis Molecular Technologies, Inc. 2022-04-07 — — US disclosed
US-9585884-B2 Pyrimidinone inhibitors of lipoprotein-associated phospholipase A2 AUSPEX PHARMACEUTICALS, INC. (US) 2017-03-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11639356-B2 Substituted imidazo[1,2-a]pyrazines and pyrazino[1,2-a]pyrimidines as topical agents for dermatological applications CREBBP, CREB1, PRKACA CTNNB1 4/4885TCF7 55/4885CLPP 3050/4885
US-20220106320-A1 TOPICAL AGENTS FOR DERMATOLOGICAL APPLICATIONS CREBBP, EBP, CREB1 CTNNB1 6/4885TCF7 74/4885CLPP 2598/4885
US-20230374020-A1 SUBSTITUTED IMIDAZO[l,2-a]PYRAZINES AND PYRAZINO[l,2-a] PYRIMIDINES AS TOPICAL AGENTS FOR DERMATOLOGICAL APPLICATIONS CREBBP, CREB1, EP300 CTNNB1 4/4885TCF7 74/4885CLPP 2590/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.